Toxoplasmosis, Parvovirus, and Cytomegalovirus in Pregnancy

Clinics in Laboratory Medicine

Volumn 36, Issue 2, 2016, Pages 407-419

  Feldman, Deborah M ^a   Keller, Rebecca ^a   Borgida, Adam F ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Diagnosis; Management; Parvovirus; Toxoplasmosis

Indexed keywords

FOLINIC ACID; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE;

AMNIOCENTESIS; CONTROLLED CLINICAL TRIAL (TOPIC); CORDOCENTESIS; CYTOMEGALOVIRUS INFECTION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS HYDROPS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN PARVOVIRUS B19; IGG AVIDITY TEST; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION SENSITIVITY; INTRAUTERINE INFECTION; MATERNAL SERUM SCREENING TEST; NEONATAL OUTCOME; NONHUMAN; PARAMETERS CONCERNING THE FETUS, NEWBORN AND PREGNANCY; PARVOVIRUS INFECTION; PATIENT EDUCATION; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK; SEROCONVERSION; SEROLOGY; TOXOPLASMA GONDII; TOXOPLASMOSIS; VERTICAL TRANSMISSION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; PARVOVIRIDAE INFECTIONS; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; TOXOPLASMOSIS, CONGENITAL;

CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PARVOVIRIDAE INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; TOXOPLASMOSIS, CONGENITAL;

EID: 84960971018     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2016.01.011     Document Type: Review

References (69)

1. Jones J., Kruszon-Moran D., Wilson M. Toxoplasma gondii infection in the United States, 1999-2000. Emerg Infect Dis 2003, 9(11):1371-1374. Available at:, Accessed October 22, 2009. http://www.cdc.gov/ncidod/EID/vol9no11/03-0098.htm.
2. Jones J., Dargelas V., Roberts J., et al. Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis 2009, 49:878-884.
3. Guerina N.G., Hsu H.-W., Meissner H., et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 1994, 330:1858-1863.
4. McClure E., Goldenberg R. Infection and stillbirth. Semin Fetal Neonatal Med 2009, 14:182-189.
5. Centers for Disease Control and Prevention Preventing congenital toxoplasmosis. MMWR Recomm Rep 2000, 49:57-75.
6. Montoya J., Remington J. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2008, 47:554-566.
7. Wilson C.B., Remington J.S., Stagno S., et al. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980, 66:767-774.
8. Montoya J., Rosso F. Diagnosis and management of toxoplasmosis. Clin Perinatol 2005, 32:705-726.
9. Del Bono V., Canessa A., Bruzzi P., et al. Significance of specific immunoglobulin M in the chronological diagnosis of 38 cases of toxoplasmic lymphadenopathy. J Clin Microbiol 1989, 27:2133-2135.
10. Ashburn D., Evans R., Skinner L.J., et al. Comparison of relative uses of commercial assays for Toxoplasma gondii IgM antibodies. J Clin Pathol 1992, 45(6):483-486.
11. Liesenfeld O., Press C., Montoya J.G., et al. False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol 1997, 35(1):174-178.
12. Liesenfeld O., Montoya J., Tathineni N., et al. Confirmatory serologic testing for acute toxoplasmosis and the rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers. Am J Obstet Gynecol 2001, 184:140-145.
13. Lequin R.M. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem 2005, 51:2415-2418.
14. Lefevre-Pettrazzoni M., Le Cam S., Wallon M. Delayed maturation of immunoglobulin G avidity: implication for the diagnosis of toxoplasmosis in pregnant women. Eur J Clin Microbiol Infect Dis 2006, 25:687-693.
15. Byrne J.L. Toxoplasmosis. Diagnostic imaging obstetrics 2011, 14-18. Amirsys Publishing, Manitoba, Canada, 14-9. 2nd edition. P.J. Woodward, A. Kennedy, R. Sohaey (Eds.).
16. Romand S., Wallon M., Franck F., et al. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol 2001, 97:296-300.
17. Foulon W., Pinon J., Stray-Pederson B., et al. Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. Am J Obstet Gynecol 1999, 181:843-847.
18. Bessieres M., Berrebi A., Cassaing S., et al. Diagnosis of congenital toxoplasmosis: prenatal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis. Mem Inst Oswaldo Cruz 2009, 104:389-392.
19. Peyron F., Wallon M., Liou C., et al. Treatments for toxoplasmosis in pregnancy. Cochrane Database Syst Rev 1999, (3). CD001684.
20. Cook G. Use of antiprotozoan and anthelmintic drugs during pregnancy: side effects and contra-indications. J Infect 1992, 25:1-9.
21. Peters P.J., Thigpen M.C., Parise M.E., et al. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf 2007, 30:481-501.
22. Bachmeyer C., Mouchnino G., Thulliez P., et al. Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation. J Infect 2006, 52:e55-e57.
23. Jones J., Ogunmodede G., Scheftel J., et al. Toxoplasmosis-related knowledge and practices among pregnant women in the United States. Infect Dis Obstet Gynecol 2003, 11:139-145.
24. Ross D., Rasmussen S., Cannon M., et al. Obstetrician/gynecologists' knowledge, attitudes, and practices regarding prevention of infections in pregnancy. J Womens Health 2009, 18:1187-1193.
25. Breugelmans M., Naessens A., Foulon W. Prevention of toxoplasmosis during pregnancy-an epidemiologic survey over 22 consecutive years. J Perinat Med 2004, 32:211-214.
26. Brown K.E. Parvovirus infections. Harrison's principles of internal medicine 2012, 1478-1479. McGraw-Hill, New York. 18th edition. D.L. Longo, A.S. Fauci, D.L. Kasper (Eds.).
27. Chorba T., Coccia P., Holman R.C., et al. The role of parvovirus B19 in anaplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986, 154:383-393.
28. Thurn J. Human parvovirus B19: historical and clinical review. Rev Infect Dis 1988, 10:1005-1011.
29. Rodis J.F., Hodick T.J., Quinn D.L., et al. Human parvovirus in pregnancy. Obstet Gynecol 1988, 72(5):733-738.
30. Anderson L.J., Tsou C., Parker R.A., et al. Detection antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986, 24:522-526.
31. Hall S.M., Cohen B.J., Mortimer P.P., et al. Prospective study of human parvovirus (B19) infection in pregnancy. Public health laboratory service working party on fifth disease. BMJ 1990, 300(6733):1166-1170.
32. Lamont R.F., Sobel J.D., Vaisbuch E., et al. Parvovirus B19 infection in human pregnancy. BJOG 2011, 118:175-186.
33. Rodis J.F., Quinn D.L., Gary G.W., et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 1990, 163(4 Pt 1):1168-1171.
34. Riipinen A., Vaisanen E., Nuutila M., et al. Parvovirus B19 infection in fetal deaths. Clin Infect Dis 2008, 47(12):1519-1525.
35. Kovacs B.W., Carlson D.E., Shahbahrami B., et al. Prenatal diagnosis of human parvovirus B19 in nonimmune hydrops fetalis by polymerase chain reaction. Am J Obstet Gynecol 1992, 167:461-466.
36. Crane J., Mundle W., Boucoiran I., et al. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can 2014, 36(12):1107-1116. Maternal Fetal Medicine Committee.
37. Levy R., Weissman A., Blomberg G., et al. Infection by parvovirus B 19 during pregnancy: a review. Obstet Gynecol Surv 1997, 52:254-259.
38. Moise K.J. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am J Obstet Gynecol 2008, 198(2):161.e1-161.e4.
39. Borna S., Mirzaie F., Hanthoush-Zadeh S., et al. Middle cerebral artery peak systolic velocity and ductus venosus velocity in the investigation of nonimmune hydrops. J Clin Ultrasound 2009, 37(7):385-388.
40. Rodis J.F., Borgida A.F., Wilson M., et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the society of perinatal obstetricians. Am J Obstet Gynecol 1998, 79(4):985-988.
41. Schild R.L., Bald R., Plath H., et al. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 1999, 13(3):161-166.
42. Odibo A.O., Campbell W.A., Feldman D.M., et al. Resolution of human parvovirus B19-induced nonimmune hydrops after intrauterine transfusion. J Ultrasound Med 1998, 17(9):547-550.
43. Nagel H.T., de Haan T.R., Vandenbussche F.P., et al. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007, 109(1):42-47.
44. Rodis J.F., Rodner C., Hansen A.A., et al. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet Gynecol 1998, 91(1):125-128.
45. Staras S.A., Dollard S.C., Radford K.W., et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006, 43(9):1143-1151.
46. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007, 17:253-276.
47. Institute of Medicine Committee to Study Priorities for Vaccine Development Vaccines for the 21st Century: a tool for decision making. Vaccines for the 21st Century: a tool for decision making 2000, 460. National Academy Press, Washington, DC. K.R. Stratton, J.S. Durch, R.S. Lawrence (Eds.).
48. Pass R.F. Cytomegalovirus. Viral infections in obstetrics and gynecology 1999, 35-36. Arnold, New York. D.J. Jeffries, C.N. Hudson (Eds.).
49. Fowler F.B., Stagno S., Pass R.F., et al. The outcome of congenital cytomegalovirus in relation to maternal antibody status. N Engl J Med 1992, 326:663-667.
50. Boppana S.B., Pass R.F., Britt W.J., et al. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 1992, 11:93-99.
51. Fowler K.B., Dahle A.J., Boppana S.B., et al. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr 1999, 135:60-64.
52. Gindes L., Teperberg-Oikawa M., Sherman D., et al. Congenital cytomegalovirus infection following primary maternal infection in the third trimester. BJOG 2008, 115:830-835.
53. Daiminger G.J., Bader U., Enders G. Pre- and periconceptional primary cytomegalovirus infection: risk of vertical transmission and congenital disease. Br J Obstet Gynaecol 2005, 112:166-172.
54. Leisnard C., Donner C., Brancart F., et al. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol 2000, 95:881-888.
55. Stagno S., Pass R.F., Cloud G., et al. Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus and clinical outcome. JAMA 1986, 256:1904-1908.
56. Lazzarotto T., Brojanac S., Maine G.T., et al. Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional Western blot and nine commercially available assays. Clin Diagn Lab Immunol 1997, 4:483-486.
57. Lazzarotto T., Gabrielli L., Lanari M., et al. Congenital cytomegalovirus infection: recent advances in the diagnosis of maternal infection. Hum Immunol 2004, 65:410-415.
58. Lazzarotto T., Spezzacatena P., Pradelli P., et al. Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin Diagn Lab Immunol 1997, 4:469-473.
59. Lazzarotto T., Varani S., Spezzacatena P., et al. Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnancy women at risk of transmitting cytomegalovirus. Viral Immunol 2000, 13:137-141.
60. Weiner C.P. Cordocentesis. Obstet Gynecol Clin North Am 1988, 15:283-301.
61. Lipitz S., Yagel S., Shalev E., et al. Prenatal diagnosis of fetal primary cytomegalovirus infection. Obstet Gynecol 1997, 89:763-767.
62. Guerra B., Lazzarotto T., Quarta S., et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2000, 183:476-482.
63. Ville Y. The megalovirus. Ultrasound Obstet Gynecol 1998, 12:151-153.
64. Guerra B., Simonazzi G., Puccetti C., et al. Ultrasound prediction of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2008, 198(380):e1-e7.
65. Pass R.F., Fowler K.B., Boppana S.B., et al. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 2006, 35:216-220.
66. Reullan-Eugene G., Barjot P., Campet M., et al. Evaluation of virological procedures to detect fetal human cytomegalovirus infection: avidity of IgG antibodies, virus detection in amniotic fluid and maternal serum. J Med Virol 1996, 50:9-15.
67. Nigro G., Adler S.P., La Torre R., et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353:1350-1362.
68. Muller A., Eis-Hubinger A.M., Brandhorts G., et al. Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. J Perinatol 2008, 25:74-76.
69. Cahill A.G., Odibo A.O., Stamillo D.M., et al. Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis. Am J Obstet Gynecol 2009, 201(466):e1-e7.